Skip to main content

Table 1 Characteristics of subjects by intron-8 polythymidine tract and F508del genotype

From: Asthma and COPD in cystic fibrosis intron-8 5T carriers. A population-based study

Polythymidine

9T/9T

7T/9T

7T/7T

6T/7T

5T/9T

5T/7T

5T/5T

9T/9T

7T/9T

7T/7T

5T/9T

 

Expected exon-9 skipping, %

7

13

18

≥18

43

48

78

-

-

-

-

 

F508del heterozygosity

       

yes

yes

yes

yes

P-value

Women / Men

44 / 39

841 / 699

3,818 / 3,087

2 / 2

22 / 18

171 / 137

1 / 1

13 / 10

127 / 90

4 / 1

2 / 2

0.99

Genotype frequency, %

0.9

16.9

75.6

0.0

0.4

3.4

0.0

0.3

2.4

0.1

0.0

 

Smoking before study entry, packyears*

16 ± 2.1

16 ± 0.5

15 ± 0.2

13 ± 10

18 ± 3.0

14 ± 1.1

8.4 ± 12

13 ± 4.0

14 ± 1.3

18 ± 10

14 ± 10

0.81

Age at study entry, years

46 ± 1.4

47 ± 0.3

47 ± 0.2

46 ± 6.3

47 ± 2.0

46 ± 0.7

39 ± 8.9

48 ± 2.6

48 ± 0.9

41 ± 5.6

46 ± 6.3

0.63

FEV1 at study entry, %pred.

87 ± 1.9

90 ± 0.4

90 ± 0.2

83 ± 8.8

96 ± 2.8

90 ± 1.0

84 ± 12

94 ± 3.7

89 ± 1.2

84 ± 7.9

101 ± 8.8

0.24

Smoking during follow-up, g/day

9.0 ± 1.1

8.8 ± 0.3

8.9 ± 0.1

11 ± 5.0

8.1 ± 1.6

7.5 ± 0.6

6.3 ± 7.1

7.9 ± 2.1

7.1 ± 0.7

8.0 ± 4.5

8.0 ± 5.0

0.24

Follow-up, years

23 ± 0.14

23 ± 0.03

23 ± 0.02

23 ± 0.66

23 ± 0.21

23 ± 0.08

24 ± 0.93

23 ± 0.27

23 ± 0.09

24 ± 0.59

24 ± 0.66

0.97

  1. Values are number of individuals, percentages, or mean ± SD. P-values by Pearson's χ2 test or analysis of variance. *Calculated as daily tobacco use (g/day) × duration of smoking (years) / 20 (g/pack). The average amount of tobacco used (in g/day) at the different examinations attended.